Defective proliferative potential of MSCs from pediatric myelodysplastic syndrome patients is associated with cell senescence

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 10, 2015, Pages 13059-13066

  Liu, Qinghua ^a   Zhu, Hongbo ^a   Dong, Jing ^a   Li, Helou ^a   Zhang, Hong ^a  

^a TAISHAN MEDICAL UNIVERSITY   (China)

Author keywords

Bone marrow; Cell senescence; Mesenchymal stem cells; Pediatric myelodysplastic syndromes; Proliferation

Indexed keywords

ADOLESCENT; CELL AGING; CELL CULTURE; CELL PROLIFERATION; CHILD; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MESENCHYMAL STROMA CELL; MYELODYSPLASTIC SYNDROME; PATHOLOGY; PHYSIOLOGY; PRESCHOOL CHILD;

ADOLESCENT; CELL AGING; CELL PROLIFERATION; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MYELODYSPLASTIC SYNDROMES;

EID: 84976564218     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Hasle H, Baumann I, Bergsträsser E, Fenu S, Fischer A, Kardos G, Kerndrup G, Locatelli F, Rogge T, Schultz KR, Starý J, Trebo M, van den Heuvel-Eibrink MM, Harbott J, Nöllke P, Niemeyer CM; European Working Group on childhood MDS. The International prognostic scoring system (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia 2004; 18: 2008-14.
2. Elghetany MT. Myelodysplastic syndromes in children: a critical review of issues in the diagnosis and classification of 887 cases from 13 published series. Arch Pathol Lab Med 2007; 131: 1110-16.
3. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G, Head DR. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003; 17: 277-82.
4. Hasle H, Niemeyer CM. Advances in the prognostication and management of advanced MDS in children. Br J Haematol 2011; 154: 185-95.
5. Nolte F and Hofmann WK. Myelodysplastic syndromes: molecular pathogenesis and genomic changes. Ann Hematol 2008; 87: 777-95.
6. Tauro S, Hepburn MD, Peddie CM, Bowen DT, Pippard MJ. Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromes. Leukemia 2002; 16: 785-90.
7. Pavlaki K, Pontikoglou CG, Demetriadou A, Batsali AK, Damianaki A, Simantirakis E, Kontakis M, Galanopoulos A, Kotsianidis I, Kastrinaki MC, Papadaki HA. Impaired proliferative potential of bone marrow mesenchymal stromal cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway. Stem Cells Dev 2014; 23: 1568-81.
8. Aanei CM, Eloae FZ, Flandrin-Gresta P, Tavernier E, Carasevici E, Guyotat D, Campos L. Focal adhesion protein abnormalities in myelodysplastic mesenchymal stromal cells. Exp Cell Res 2011; 317: 2616-29.
9. Wang Z, Tang X, Xu W, Cao Z, Sun L, Li W, Li Q, Zou P, Zhao Z. The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or high-risk myelodysplastic syndromes. PLoS One 2013; 8: e57470.
10. Blau O, Baldus CD, Hofmann WK, Thiel G, Nolte F, Burmeister T, Türkmen S, Benlasfer O, Schümann E, Sindram A, Molkentin M, Mundlos S, Keilholz U, Thiel E, Blau IW. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct distinct genetic abnormalities compared with leukemic blasts. Blood 2011; 118: 5583-92.
11. Geyh S, Oz S, Cadeddu RP, Fröbel J, Brückner B, Kündgen A, Fenk R, Bruns I, Zilkens C, Hermsen D, Gattermann N, Kobbe G, Germing U, Lyko F, Haas R, Schroeder T. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 2013; 27: 1841-51.
12. Zhao ZG, Xu W, Yu HP, Fang BL, Wu SH, Li F, Li WM, Li QB, Chen ZC, Zou P. Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes. Cancer Lett 2012; 317: 136-43.
13. Klaus M, Stavroulaki E, Kastrinaki MC, Fragioudaki P, Giannikou K, Psyllaki M, Pontikoglou C, Tsoukatou D, Mamalaki C, Papadaki HA. Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells Develop 2010; 19: 1043-54.
14. Flores-Figueroa E, Montesinos JJ, Flores-Guzmán P, Gutiérrez-Espíndola G, Arana-Trejo RM, Castillo-Medina S, Pérez-Cabrera A, Hernández-Estévez E, Arriaga L, Mayani H. Functional analysis of myelodysplastic syndromes derived mesenchymal stem cells. Leukemia Res 2008; 32: 1407-16.
15. Flores-Figueroa E, Arana-Trejo RM, Gutiérrez-Espíndola G, Pérez-Cabrera A, Mayani H. Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. Leukemia Res 2005; 29: 215-24.
16. Lopez-Villar O, Garcia JL, Sanchez-Guijo FM, Robledo C, Villaron EM, Hernández-Campo P, Lopez-Holgado N, Diez-Campelo M, Barbado MV, Perez-Simon JA, Hernández-Rivas JM, San-Miguel JF, del Cañizo MC. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q-syndrome. Leukemia 2009; 23: 664-72.
17. Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003; 33: 919-26.
18. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872-85.
19. Raaijmakers MH. Myelodysplastic syndromes: revisiting the role of the bone marrow microenvironment in disease pathogenesis. Int J Hematol 2012; 95: 17-25.
20. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-7.
21. Sethe S, Scutt A, Stolzing A. Aging of mesenchymal stem cells. Ageing Res Rev 2006; 5: 91-116.
22. Zhou S, Greenberger JS, Epperly MW, Goff JP, Adler C, Leboff MS, Glowacki J. Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell 2008; 7: 335-43.
23. Stolzing A, Jones E, McGonagle D, Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev 2008; 129: 163-73.
24. Bonab MM, Alimoghaddam K, Talebian F, Ghaffari SH, Ghavamzadeh A, Nikbin B. Aging of mesenchymal stem cell in vitro. BMC Cell Biol 2006; 7: 14.
25. Yoon DS, Kim YH, Jung HS, Paik S, Lee JW. Importance of Sox2 in maintenance of cell proliferation and multipotency of mesenchymal stem cells in low-density culture. Cell Prolif 2011; 44: 428-40.